Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit

Journal of Immunology

Volumn 158, Issue 8, 1997, Pages 3936-3946

  Ågren, Lena C ^a   Ekman, Lena ^a   Löwenadler, Björn ^b   Lycke, Nils Y ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; VACCINE;

ANIMAL; ARTICLE; B LYMPHOCYTE; C57BL MOUSE; DRUG EFFECT; FEMALE; IMMUNOLOGY; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; CHOLERA TOXIN; FEMALE; IMMUNOGLOBULIN M; MICE; MICE, INBRED C57BL; VACCINES; VACCINES, SYNTHETIC;

EID: 0031569528     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Kingsley, G., J. Lanchbury, and G. Panayi. 1996. Immunotherapy in rheumatic disease: an idea whose time has come - or gone? Immunol. Today 17:9.
2. Röcken, M., M. Racke, and E. M. Shevach. 1996. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 17:225.
3. Daynes, R. A., B. A. Araneo, J. Hennebold, E. Enioutina, and H. H. Mu. 1995. Steroids as regulators of the mammalian immune response. J. Invest. Dermatol. 105:14S.
4. Thrush, G. R., L. R. Lark, B. C. Clinchy, and E. S. Vitetta. 1996. Immunotoxins: an update. In Annu. Rev. Immunol. 14:49.
5. Vogel, F. R. 1995. Immunologic adjuvants for modern vaccine formulations. Ann. NY Acad. Sci. 754:153.
6. Allison, A. C., and N. E. Byars. 1990. Adjuvants for a new generation of vaccines. In New Generation Vaccines. G. C. Woodrow, and M. M. Levine, eds. Marcel Dekker, New York, p. 129.
7. Elson, C. O., and M. T. Dertzbaugh. 1994. Mucosal adjuvants. In Handbook of Mucosal Immunology. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, and J. Bienenstock, eds. Academic Press, San Diego, p. 391.
8. Lycke, N. 1996. A molecular approach to the construction of an effective mucosal vaccine adjuvant: studies based on cholera toxin ADP-ribosylation and cell targeting. In Essentials of Mucosal Immunity. M. Kagnoff and H. Kiyono, eds. Academic Press, San Diego, p. 563.
9. Vogel, F. R., and M. F. Powell. 1995. A compendium of vaccine adjuvants and excipients. In Vaccine Design. M. F. Powell and M. J. Newman, eds. Plenum Publishing, New York, pp. 412-413.
10. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
11. Elson, C. D., and W. Ealding. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132:27.
12. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301.
13. Liang, X. P., M. E. Lamm, and J. G. Nedrud. 1988. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J. Immunol. 141:1495.
14. M1 pentasaccharide. Protein Sci. 3:166.
15. Sixma, T. K., K. H. Kalk, B. A. van Zanten, Z. Dauter, J. Kingma, B. Witholt, W. G. Hol. 1993. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol. 230:890.
16. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clemens. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510.
17. Wu, H. Y., and M. W. Russell. 1993. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61:314.
18. Vadolas, J., J. K. Davies, P. J. Wright, and R. A. Strugnell. 1995. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 25:969.
19. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is finked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277.
20. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. 1996. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:974.
21. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
22. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644.
23. Ljungberg, U. K., B. Jansson, U. Niss, R. Nilsson, B. E. Sandberg, and B. Nilsson. 1993. The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab′)2: separation of affinity from specificity. Mol. Immunol. 30:1279.
24. Nilsson, B., T. Moks, B. Jansson, L. Abrahamsén, A. Elmblad, E. Holmgren, C. Henrichson, A. T. Jones, and M. Uhlén. 1987. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1:107.
25. Boyer, H. W., and D. Roulland-Dussiox. 1969. A complementation analysis of the restriction and modification of DNA in Escherichia coli. J. Mol. Biol. 41:459.
26. Mekalanos, J. J. 1983. Duplication and amplification of toxin genes in Vibrio cholerae. Cell 35:253.
27. Sanger, F., S. Niclen, and A. R. Coulson. 1977. DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463.
28. Erlich, H. 1989. PCR Technology: Principles and Applications for DNA Amplification. W. H. Freeman, New York, p. 1.
29. Svennerholm, A. M., M. Wikstrom, M. Lindblad, and J. Holmgren. 1986. Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin. Med. Biol. 64: 23.
30. Tsuji, T., T. Inoue, A. Miyama, and M. Noda. 1991. Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity. Febs Lett. 291:319.
31. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J.-P. Kraehenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:15.
32. Bromander, A. K., L. Ekman, M. Kopf, J. G. Nedrud, and M. Y. Lycke. 1996. IL-6 deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J. Immunol. 156:4290.
33. Hornquist, E., and N. Lycke. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:2136.
34. Lange, S., and J. Holmgren. 1978. Protective antitoxic cholera immunity in mice: influence of route and number of immunizations and mode of action of protective antibodies. Acta Pathol. Microbiol. Scand. Sect. C Immunol. 86:145.
35. Lexomboon, U., P. Mansuwan, C. Duangmani, P. Benjadol, and M. c. MT. 1972. Clinical evaluation of co-trimoxazole and furazolidone in treatment of shigellosis in children. Br. Med. J. 3:23.
36. Domerighini, M., C. Montecucco, W. C. Ripka, and R. Rappuoli. 1991. Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding. Mol. Biol. 5:23.
37. Young, W. J., Y. Tamura, D. M. Wolock, and J. W. Fox. 1984. Staphylococcal protein A binding to the Fab fragments of mouse monoclonal antibodies. J. Immunol. 133:3163.
38. Roben, P. W., A. N. Salem, and G. J. Silverman. 1995. VH3 family antibodies bind domain D of staphylococcal protein A. J. Immunol. 154:6437.
39. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immun. Today 17:138.
40. + T cells: ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J. Immunol. 155:45.
41. Jenkins, M. K. 1994. The ups and downs of T cell costimulation. Immunity 1:443.
42. Allison, J. P. 1994. CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6:414.
43. + T lymphocytes to peptide antigen in vivo. J. Immunol. 151:6742.
44. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol 11:191.
45. + T cells to protein antigens in vivo. J. Immunol. 155:3734.
46. Faassen, A. E., and S. K. Pierce. 1995. Cross-linking cell surface class II molecules stimulates Ig-mediated B cell antigen processing. J. Immunol. 155:1737.
47. DeBenedette, M. A., N. R. Chu, K. E. Pollok, J. Hurtado, W. F. Wade, B. S. Kwon, and T. H. Watts. 1995. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J. Exp. Med. 181:985.
48. Chen, C., D. A. Faherty, A. Gault, S. E. Connaughton, G. D. Powers, D. I. Godfrey, and N. Nabavi. 1994. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J. Immunol. 152:2105.
49. Murphy, J. R., and D. P. Williams. 1991. Protein engineering of microbial toxins: design and properties of novel fusion proteins with therapeutic and immunogenic potential. In Sourcebook of Bacterial Toxins. J. E. Alouf and J. H. Freer, eds. Academic Press, San Diego, p. 491.
50. Lencer, W. I., S. Moe, P. A. Rufo, and J. L. Madara. 1995. Transcytosis of cholera toxin subunits across model human intestinal epithelia. Proc. Natl. Acad. Sci. USA 92:10094.
51. Lencer, W. I., C. Constable, S. Moe, M. G. Jobling, H. M. Webb, S. Ruston, J. L. Madara, T. R. Hirst, and R. K. Holmes. 1995. Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J. Cell. Biol. 131:951.
52. Cieplak, W., Jr, R. J. Messer, M. E. Konkel, and C. C. R. Grant. 1995. Role of a potential endoplasmic reticulum retention sequence (RDEL) and the Golgi complex in the cytotonic activity of Escherichia coli heat-labile enterotoxin. Mol. Microbiol. 16:789.
53. M1-receptor binding enhances later events in differentiation. J. Immunol. 150:4810.
54. Munoz, E., A. M. Zubiaga, M. Merrow, N. P. Sauter, and B. T. Huber. 1990. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T celt proliferation. J. Exp. Med. 172:95.
55. Elson, C. O., S. P. Holland, M. T. Dertzbaugh, C. F. Cuff, and A. O. Anderson. 1995. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J. Immunol. 154:1032.
56. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908.
57. Matousek, M. P., J. G. Nedrud, and C. V. Harding. 1996. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. J. Immunol. 156: 4137.
58. Cassell, D. J., and R. H. Schwartz. 1994. A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing co-stimulation. J. Exp. Med. 180:1829.
59. Ronchese, F., and B. Hausmann. 1993. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J. Exp. Med. 177: 679.
60. Stockinger, B., T. Zal, A. Zal, and D. Gray. 1996. B cells solicit their own help from T cells. J. Exp. Med. 183:891.
61. Cong, Y., and C. O. Elson. 1996. Cholera toxin enhances co-stimulatory activity of macrophages by differentially regulating B7.1 and B7.2 expression. FASEB 10:6 Abstr. A1343.